The Endoform partnership between AROA Biosurgery and Mölnlycke Healthcare US gives the wound-care product an additional commercial channel in U.S. post-acute settings. The exclusive co-promotion agreement took effect on October 16, 2026. AROA retains ownership and responsibility for manufacturing, distribution and supply, while its FY27 financial guidance remains unchanged.
Key Takeaways
- Mölnlycke will co-promote Endoform exclusively in U.S. post-acute settings.
- AROA keeps Endoform and its underlying technology, with international arrangements unchanged.
- The agreement allows AROA to focus resources on Myriad and Symphony without changing FY27 guidance.
Table of Contents
- Endoform partnership targets U.S. post-acute care
- AROA keeps ownership and supply responsibilities
- FY27 outlook remains unchanged
- Conclusion
Endoform partnership targets U.S. post-acute care
AROA’s exclusive U.S. co-promotion agreement combines Endoform and its proprietary AROA ECM technology with Mölnlycke’s wound-care expertise and commercial reach. The companies intend to make the product available to more clinicians and patients and support its continued growth.
Endoform products are extracellular matrix products used to manage acute and chronic wounds in outpatient or post-acute settings. The agreement covers only the U.S. post-acute market, rather than AROA’s entire product portfolio.
Mölnlycke Vice President Americas Craig Kennedy said adding Endoform to the company’s advanced wound-dressing portfolio would expand the solutions available to clinicians. Broader access is an objective of the arrangement, not a reported sales or clinical outcome.
| Item | Details |
|---|---|
| Effective date | October 16, 2026 |
| Agreement scope | Exclusive Endoform co-promotion in U.S. post-acute settings |
| FY27 revenue guidance | NZ$115 million–NZ$125 million; unchanged |
| FY27 normalized EBITDA guidance | NZ$8 million–NZ$11 million; unchanged |
AROA keeps ownership and supply responsibilities
The deal is a commercial collaboration, not a sale of Endoform. AROA retains ownership of both the product and AROA ECM technology and will continue to manufacture, distribute and supply Endoform.
AROA’s other product portfolios and commercial arrangements remain unchanged, including Endoform distribution outside the United States. That limits the scope of the operational change to promotion in the specified U.S. care setting.
Founder and Chief Executive Brian Ward said the arrangement would allow AROA to concentrate its efforts on sustaining Myriad’s growth in surgical settings and pursuing the opportunity for Symphony in outpatient wound care.
FY27 outlook remains unchanged
AROA maintained its FY27 guidance for total revenue of NZ$115 million to NZ$125 million and normalized EBITDA of NZ$8 million to NZ$11 million. These figures are management’s outlook, not reported financial results.
The unchanged forecast means the partnership announcement does not include an upgrade to expected FY27 performance. Its immediate significance is the change in promotional support for Endoform and the resulting ability to focus AROA’s resources on other products.
Conclusion
With the agreement effective, attention turns to its implementation in U.S. post-acute care. AROA’s unchanged FY27 guidance remains the stated financial benchmark.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
